BioMarin Pharmaceuticals BMRN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $105.53M-43.2% | —— | -$30.74M-129% | $240.53M+124% | $185.69M+109% | ||
| $16.41M-25.6% | $20.44M-13.4% | $18.49M-2.7% | $18.56M-29.9% | $22.07M-19.3% | ||
| $43.46M+15.3% | $46.91M-9.6% | $49.27M+13.3% | $47.53M-0.8% | $37.7M-35.3% | ||
| $9.22M-67.6% | $613K-98.6% | —— | $33.34M+2,563% | $28.43M+9,875% | ||
| $6.09M+822% | $653K-1.1% | $649K-9.6% | $660K-33.4% | $660K-33.3% | ||
| $0-100% | $122.05M— | —— | —— | $2.97M— | ||
| $7.16M-87.6% | $120.68M— | —— | $98.53M+87.0% | $57.59M+1,601% | ||
| -$44.49M-283% | $18.13M-47.1% | $26.33M— | $48.13M+57.3% | $24.34M+44.7% | ||
| $3.1M+217% | —— | $116.37M-4.8% | $5.77M— | -$2.66M+95.5% | ||
| -$1.48M-191% | $5.89M-85.9% | $19.17M+114% | $11.88M+10.5% | $1.62M-86.6% | ||
| $8.7M+321% | —— | $16.36M+365% | $3.47M+2.0% | $2.07M-37.5% | ||
| $5.37M+324% | $2.71M+113% | $0-100% | $649K-34.1% | $1.27M+1,098% | ||
| $11.55M+82.6% | -$41.02M— | $17.03M-21.0% | $8.77M+146% | $6.33M-63.5% | ||
| $220.65M+26.5% | $99.64M-46.3% | $368.69M+66.5% | $185.27M+56.0% | $174.39M+271% | ||
| $20.92M+24.8% | $40.72M+109% | $28.45M+54.1% | $17.1M-19.8% | $16.77M-35.8% | ||
| $25.79M-71.1% | $42.61M-26.4% | $110.83M-29.4% | $113.16M+53.3% | $89.27M-26.6% | ||
| $767.28M+886% | $43.25M-72.0% | $98.81M-38.5% | $117.93M-36.6% | $77.8M-40.8% | ||
| -$4.97M— | $0+100% | —— | —— | $0+100% | ||
| $725.53M+2,669% | -$42.45M-156% | -$330.96M— | -$12.59M-114% | -$28.24M-98.4% | ||
| $850M— | —— | —— | —— | $0— | ||
| $28.18M-27.3% | $2.7M-45.0% | $2.18M-63.2% | $12.31M-26.7% | $38.78M-22.4% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $813.17M+2,197% | $0— | -$2.17M+99.6% | -$4.6M— | -$38.78M+9.4% | ||
| $1.41M+200% | —— | —— | -$3.06M-193% | -$1.42M-173% | ||
| $1.76B+1,562% | $61.57M-77.0% | $36.29M+112% | $165.01M-26.7% | $105.96M+1,403% | ||
| $14.64M+41.0% | $26M+22.7% | $7.82M-40.8% | $52M+153% | $10.39M+351% | ||
| $455K-66.6% | $1.11M-35.9% | $978K-49.6% | $1.36M-37.7% | $1.36M-45.6% | ||
| $6.09M+822% | $653K-1.1% | $649K-9.6% | $660K-33.4% | $660K-33.3% | ||
| $0-100% | $122.05M— | —— | —— | $2.97M— | ||
| -$6.71M-167% | -$4.22M— | -$5.55M-332% | -$4.72M-152% | $10.03M-7.2% | ||
| $11.55M+82.6% | -$41.02M— | $17.03M-21.0% | $8.77M+146% | $6.33M-63.5% | ||
| $5.37M+324% | $2.71M+113% | $0-100% | $649K-34.1% | $1.27M+1,098% | ||
| -$4.97M— | $0+100% | —— | —— | $0+100% | ||
| $767.28M+886% | $43.25M-72.0% | $98.81M-38.5% | $117.93M-36.6% | $77.8M-40.8% | ||
| $8.65M— | —— | —— | —— | $0— | ||
| $850M— | —— | —— | —— | $0— | ||
| $4.48M— | —— | —— | —— | $0-100% | ||
| $199.73M+26.7% | $58.92M-64.5% | $340.24M+67.6% | $168.17M+72.6% | $157.63M+655% | ||
| $199.73M+26.7% | $58.92M-64.5% | $340.24M+67.6% | $168.17M+72.6% | $157.63M+655% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioMarin Pharmaceuticals generate?
- BioMarin Pharmaceuticals (BMRN) generated $874.3M in operating cash flow over the trailing twelve months.
- What is BioMarin Pharmaceuticals's free cash flow?
- After $107.2M of capital expenditures, BioMarin Pharmaceuticals's free cash flow was $767.1M over the trailing twelve months, up 22.9% year over year.
- Where does BioMarin Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioMarin Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
